EX-Dividend Schedule: Cardinal Health Raised its Dividend By 3%; Will Trade Ex-Dividend on June 29, 2018

LONDON, UK / ACCESSWIRE / June 28, 2018 / Active-Investors has a free review on Cardinal Health, Inc. (NYSE: CAH) following the Company’s announcement that it will begin trading ex-dividend on June 29, 2018. To capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on June 28, 2018. Active-Investors has initiated due-diligence on this dividend stock. Register with us for more free research including the one on CAH:

www.active-investors.com/registration-sg/?symbol=CAH

If your portfolio includes dividend stocks, you have come to the right place for timely information. All you need to do is sign up for your free membership at:

www.active-investors.com/registration-sg

Dividend Declared

On May 09, 2018, Cardinal Health’s Board of Directors approved a 3% increase in the Company’s quarterly dividend from $0.4624 per share to $0.4763 per share. The dividend will be payable on July 15, 2018, to shareholders of record on July 02, 2018.

Cardinal Health’s indicated dividend represents a yield of 3.57%, which is substantially higher than the average dividend yield of 1.86% for the Services sector. The Company has raised its dividend for thirteen years in a row.

Dividend Insights

Cardinal Health has a dividend payout ratio of 38.7%, which means that the Company spends approximately $0.39 for dividend distribution out of every $1.00 earned. The dividend payout ratio reflects how much amount a company is returning to shareholders versus how much money it is keeping on hand to reinvest in growth, to pay off debt, and/or to add to its cash reserves.

As per analysts’ estimates, Cardinal Health is forecasted to report earnings of $5.25 per share for the next year, which is more than double compared to the Company’s annualized dividend payout of $1.91 per share.

As of March 31, 2018, Cardinal Health’s cash and equivalents totaled $2.18 billion compared to $6.88 billion as on June 30, 2017. For the third quarter fiscal 2018, the Company’s net cash provided by operating activities was $754 million compared to negative $198 million for the year ago same period. The Company’s strong financial position indicates its ability to absorb any fluctuations in earnings and cash flow and to sustain the dividend distribution for a long period.

Recent Development for Cardinal Health

On June 12, 2018, Cardinal Health announced that the US Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has provided a favorable recommendation on the premarket approval application for INCRAFT® AAA Stent Graft System (INCRAFT). The panel voted 11 to 4 in favor of the benefits of the INCRAFT® system.

The INCRAFT system is an advanced endovascular aneurysm repair (EVAR) technology for the treatment of infrarenal abdominal aortic aneurysms (AAAs), a severe, and complex condition.

About Cardinal Health, Inc.

Cardinal Health is a global, integrated healthcare services and products Company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices worldwide. The Company provides clinically proven medical products, pharmaceuticals, and cost-effective solutions that enhance supply chain efficiency from hospital to home. Backed by nearly 100 years of experience, with approximately 50,000 employees in nearly 60 countries, Cardinal Health ranks #14 on the Fortune 500.

Stock Performance Snapshot

June 27, 2018 – At Wednesday’s closing bell, Cardinal Health’s stock slightly declined 0.73%, ending the trading session at $52.93.

Volume traded for the day: 1.70 million shares.

Stock performance in the last month – up 2.28%

After yesterday’s close, Cardinal Health’s market cap was at $16.53 billion.

Price to Earnings (P/E) ratio was at 21.40.

The stock has a dividend yield of 3.61%.

The stock is part of the Services sector, categorized under the Drugs Wholesale industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 503947